All In Biotech

Drug Trial Radar · NCT04886154

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)

Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,440

Actual

Start

Jun 14, 2021

Primary completion

Feb 2, 2024

Study completion Feb 2, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety, effectiveness, and immune response of the meningococcal combined ABCWY vaccine (GSK4023393A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups. The first time-in-human (FTIH), Phase I part of this study was conducted in healthy adults in a dose-escalating fashion with 2 formulations of the investigational MenABCWY-2Gen vaccine and served as a safety lead-in to the Phase II study. The Phase II part of the study was conducted in 2 parts: The 'formulation and schedule-finding' part followed in healthy adolescents and young adults and was designed to select the vaccine formulation and the schedule to be tested in Phase III. The 'blood sourcing' part was conducted in healthy adults in order to collect sufficient serum samples for the development of assays to be used in the MenABCWY-2Gen vaccine clinical development program.

Conditions

  • Infections, Meningococcal

Interventions

  • MenABCWY-2Gen low dose vaccineCombination product

    MenABCWY-2Gen low dose vaccine is administered intramuscularly as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose\_06 Group and ABCWY low dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose\_01 Group, ABCWY low doseS\_02 Group and ABCWY low doseS\_06 Group in study Phase II (Sourcing).

  • MenABCWY-2Gen high dose vaccineCombination product

    MenABCWY-2Gen high dose vaccine is administered intramuscularly 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose\_06 Group and ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose\_01 Group, ABCWY high doseS\_02 Group and ABCWY high doseS\_06 Group in study Phase II (Sourcing).

  • PlaceboCombination product

    Placebo is administered intramuscularly as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose\_06 Group, ABCWY low dose\_02 Group, ABCWY high dose\_06 Group, ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding).

  • MenB vaccineCombination product

    MenB vaccine is administered intramuscularly as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).

  • MenACWY vaccineBiological

    MenACWY vaccine is administered intramuscularly as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Administration Site Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
  2. Number of Participants With Solicited Administration Site Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
  3. Number of Participants With Solicited Systemic Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
  4. Number of Participants With Solicited Systemic Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
  5. Number of Participants With Any Unsolicited Adverse Events (AEs), Including All Serious Adverse Events (SAEs), AEs Leading to Withdrawal and AEs of Special Interest (AESIs) in Study Phase I (Safety Lead-in)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 1
  6. Number of Participants With Any Unsolicited AEs, Including All SAEs, AEs Leading to Withdrawal and AESIs in Study Phase I (Safety Lead-in)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 31
  7. Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase I (Safety Lead-in)Time frame: Throughout the Phase 1 study period (Day 1 through Day 211)
  8. Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values, in Study Phase I (Safety Lead-in)Time frame: At Day 8 (7 days after the first vaccination)
  9. Number of Participants With Clinically Significant Haematological and Biochemical Laboratory Values, in Study Phase I (Safety Lead-in)Time frame: At Day 8 (7 days after the first vaccination)
  10. Percentage of Blood Samples With Bactericidal Serum Activity Using Enc-hSBA Against a Panel of 110 Randomly Selected Endemic US N. Meningitidis Serogroup B Invasive Disease Strains at Study Phase II (Formulation and Schedule-finding)Time frame: At Day 211 (1 month after the last vaccination)
  11. Number of Participants With a 4-fold Rise in hSBA Titers Against Serogroups A, C, W and Y in Study Phase II (Formulation and Schedule-finding)Time frame: At Day 211 for ABCWY groups (1 month after the last MenABCWY-2Gen vaccination) and at Day 31 for Control group (1 month after the last MenACWY vaccination)
  12. Number of Participants With Solicited Administration Site Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
  13. Number of Participants With Solicited Administration Site Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 121
  14. Number of Participants With Solicited Administration Site Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
  15. Number of Participants With Solicited Systemic Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
  16. Number of Participants With Solicited Systemic Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 121
  17. Number of Participants With Solicited Systemic Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
  18. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Formulation and Schedule-finding)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 1
  19. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Formulation and Schedule-finding)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 121
  20. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Formulation and Schedule-finding)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 181
  21. Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Formulation and Schedule-Finding)Time frame: Throughout the Phase II FSF study period (Day 1 through Day 541)
  22. Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
  23. Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
  24. Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 61
  25. Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
  26. Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
  27. Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
  28. Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 61
  29. Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
  30. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 1
  31. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 31
  32. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 61
  33. Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 181
  34. Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Sourcing)Time frame: Throughout the study period (Day 1 through Day 211)
  35. Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Sourcing)Time frame: Throughout the study period (Day 1 through Day 241)
  36. Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Sourcing)Time frame: Throughout the study period (Day 1 through Day 361)

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Longmont, Colorado

  • GSK Investigational Site

    Doral, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Meridian, Idaho

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Springfield, Missouri

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Fortitude Valley, Queensland, Australia

  • GSK Investigational Site

    Taringa, Queensland, Australia

  • GSK Investigational Site

    Tarragindi, Queensland, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Spearwood, Western Australia, Australia

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Linkebeek, Belgium

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    Salvador, Brazil

  • GSK Investigational Site

    São José do Rio Preto, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Elblag, Poland

  • GSK Investigational Site

    Katowice, Poland

  • GSK Investigational Site

    Katowice, Poland

  • GSK Investigational Site

    Krakow, Poland

  • GSK Investigational Site

    Krakow, Poland

  • GSK Investigational Site

    Luboń, Poland

  • GSK Investigational Site

    Siemianowice Śląskie, Poland

  • GSK Investigational Site

    Tarnów, Poland

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.